Wyeth

 

Five Giralda Farms
Madison, NJ 07940

USA

Phone: (973) 660-5000
Fax: (973) 660-5771

Email:
Web Site: http://www.wyeth.com

 

A. Company Profile

 

Wyeth (NYSE: WYE) is one of world's leading pharmaceutical companies. The company's product portfolio includes innovative treatments across a wide range of therapeutic areas. There are extensive discovery and development programs in the field of oncology at Wyeth.

 

B. Technology

 

Wyeth produced the first drug-antibody-targeted chemotherapy to be approved by the FDA. Calicheamicin, a unique enediyne-containing fermentation product, is one of the most potent antitumor agents discovered to date. It cleaves double-stranded DNA with remarkable efficiency and base-pair specificity. It is too cytotoxic to be used alone. However, conjugation of calicheamicin to an antibody specific for an acute myeloid leukemia tumor cell surface antigen was found to have reduced cytotoxic and effective antitumor activities.

 

C. Products

 

 

Product Pipelines

 

Product	Indication	Clinical Status
CMC-544	B cell non-Hodgkin's lymphoma	Phase III
CMD-193	Various tumors	Phase I
EKB-569 (HKI-272, SKI-606)	Pancreatic and colorectal cancers	Phase I
MAC-321	Colorectal and metastatic breast cancers	Phase II
Methotrxate	Various tumors	Market
MST-997 (TL909)	Various tumors	Phase I
Mylotarg	Acute myeloid leukemia	Market
Neumega	Severe thrombocytopenia	Market
Temsirolimus (Terosil, CCI-779)	Renal cancer	Market
	Breast cancers and mantle cell lymphoma	Phase III

 

1. CMC-544

 

CMC-544 is a CD22-targeted cytotoxic immunoconjugate, currently being evaluated in B-cell non-Hodgkin's lymphoma (B-NHL) patients.

 

2.CMD-193

 

CMD-193 is a humanised monoclonal antibody linked to a toxin (calicheamicin). The experimental treatment approach used involves targeting a marker (antigen) called the Lewis-y antigen on the tumour cell's surface with a specially constructed humanised monoclonal antibody. This antibody delivers a toxin (calicheamicin) into the tumour cell and this may kill the tumour cell.

2. EKB-569

 

EKB-569, 4-(3-bromoanilino)-6,7-dimethoxy-3-quinolinecarbonitrile, is an Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitor. As a cytostatic oncology drug it may be useful in tumors that overexpress EGFR. Variation of the 4-anilino group of EKB-569 provided HKI-272, a dual inhibitor of EGFR and HER-2.

 

SKI-606, initially reported to be a Src inhibitor, was found to also inhibit Abl kinase and therefore could be a potential alternative treatment to Gleevec.

3. MAC-321

 

MAC-321 is a taxane analog with demonstrated superior antitumor activities. MAC-321 is licensed from Taxolog Inc. by Wyeth. MAC-321 is believed to exert its anti-tumor cell effects through several mechanisms including tubulin binding, microtubule stabilization, apoptosis, TNF-alpha up-regulation and angiogenesis inhibition.

 

4. Methotrxate

 

Methotrxate is an antimetabolite and is used in treatment of many different tumors.

 

5. MST-997

 

MST-997, TL909, is a novel taxane with greater apparent potency in preclinical models than paclitaxel, and antitumor activity in cells that express low to moderate MDR1 levels.

 

5. Myotarg

 

Mylotarg (Gemtuzumab ozogamicin) consists of an engineered monoclonal antibody conjugated to a cytotoxic agent, calicheamicin. Current evidence has led to the belief that acute myeloid leukemia (AML) originates from malignant transformation of hematopoietic progenitor cells (which are CD33+), and not the pluripotent stem cells (which are CD33-). The murine humanized monoclonal antibody is directed against CD33, an antigen expressed in approximately 80% - 90% of cases of AML. Calicheamicin is a natural product obtained by fermentation of the organism Micromonospora echinospora ssp. calichensis. Mylotarg has been approved in the US for treatment of patients with AML in first relapse who are 60 years of age or older and who are not candidates for other cytotoxic chemotherapy.

 

6. Neumega

 

Neumega (Oprelvekin) is a platelet growth factor that can help prevent extremely low platelet counts caused by chemotherapy. Treatment with Neumega may help cancer patients continue their treatment without interruption.

 

7. Temsirolimus

 

Temsirolimus, CCI-779, is a cell cycle inhibitor that inhibits mammalian target of rapamycin (mTOR)-driven cell proliferatiion and is an ester of sirolimus (rapamycin). It has a novel anti-tumor mechanism of action resulting in the inhibition of translation of several key proteins that regulate the G1 to S phase transition of the cell cycle.

 

D. Job Opportunities at Wyeth.

 

E. Information for Investor

 

F. Others

 

 

 

 

Cell signaling pathway inhibitors:

 

 

HKI-272

SKI-606

MKI-833

 

Antibody-targeted chemotherapy:

 

 

CMC-544

CMD-193

CME-548